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Kunzang Chosdol1, Takaji Wakita3, Koichi Watashi3, Amit Awasthi4, Subrat K. Acharya5, 
Navin Khanna6, Ashutosh Tiwari2,8 & Subrata Sinha1,7
Neutralizing monoclonal antibodies are being found to be increasingly useful in viral infections. In 
hepatitis B infection, antibodies are proven to be useful for passive prophylaxis. The preS1 region (21–
47a.a.) of HBV contains the viral hepatocyte-binding domain crucial for its attachment and infection 
of hepatocytes. Antibodies against this region are neutralizing and are best suited for immune-
based neutralization of HBV, especially in view of their not recognizing decoy particles. Anti-preS1 
(21–47a.a.) antibodies are present in serum of spontaneously recovered individuals. We generated a 
phage-displayed scFv library using circulating lymphocytes from these individuals and selected four 
preS1-peptide specific scFvs with markedly distinct sequences from this library. All the antibodies 
recognized the blood-derived and recombinant preS1 containing antigens. Each scFv showed a discrete 
binding signature, interacting with different amino acids within the preS1-peptide region. Ability to 
prevent binding of the preS1 protein (N-terminus 60a.a.) to HepG2 cells stably expressing hNTCP 
(HepG2-hNTCP-C4 cells), the HBV receptor on human hepatocytes was taken as a surrogate marker for 
neutralizing capacity. These antibodies inhibited preS1-hepatocyte interaction individually and even 
better in combination. Such a combination of potentially neutralizing recombinant antibodies with 
defined specificities could be used for preventing/managing HBV infections, including those by possible 
escape mutants.
Around 350 million chronically infected individuals constitute the global disease burden of Hepatitis B and its 
related complications such as liver cirrhosis, liver failure and hepatocellular carcinoma (HCC). The high ende-
micity zones include Asia, Africa, southern Europe and Latin America. Global vaccination programs over the 
past two decades with the viral small surface protein (SHBs) containing vaccine have considerably decreased the 
overall incidence of HBV infection1,2. Also, more than 90% of adult-acquired HBV infections are spontaneously 
cleared by the qualitatively and quantitatively strong immune responses3. However, low HBV vaccine coverage 
of viral mutants, vertical transfer from infected mother, accidental exposures through needle-stick injuries, liver 
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transplantation and immune-compromised individuals accompanied with an increase in ‘viral escape mutants’ 
are responsible for the high global prevalence of this disease2,4.
The current post-exposure prophylactic measures advocate the use of plasma derived hepatitis B immune 
globulin (HBIG) in combination with HBV vaccine in the cases of accidental/perinatal HBV exposure5,6. But 
the associated issues of risk of blood-borne cross contamination, cross reactivity, low specific activity, limited 
availability and cost-effectiveness are some of the growing concerns over its long-term use7,8. The presence of 
disease concomitantly with an apparently neutralizing antibody response has been an argument against the use 
of anti-HBs antibodies in therapy. However neutralizing efficacy of anti-HBV antibodies has been demonstrated 
in non-human primates9–12.
The small Hepatitis B surface (SHBs) protein is the major component of the viral envelope which consti-
tutes the immunodominant epitope (‘a’ determinant) on viral envelope and elicits maximal neutralizing humoral 
response. However the virus evades this response by the secretion of non-infectious spherical or filamentous 
sub-viral particles in 1000–10000 fold excess over the infectious virions. These decoy particles mimic the virions 
and soak up the virus specific immune response, thereby, reducing its efficacy3,13. The spherical decoy particles 
are solely composed of SHB protein and its large excess over the virus makes anti-SHB antibodies less effective 
and are, therefore not an ideal choice for passive immunization. The other two surface proteins, middle Hepatitis 
B surface (MHBs) and large Hepatitis B surface (LHBs) proteins, have additional PreS2 (55a.a.) and PreS1 
(119/108a.a.) + PreS2 regions respectively at the N-terminus of the SHBs. The other decoy particles, secreted in 
small proportion-filamentous particles, include MHBs and LHBs proteins in addition to SHBs (L:M:S = 1:1:4)14. 
The preS1 protein which contains the viral putative hepatocyte binding domain between 21–47 amino acids is 
crucial for viral attachment and entry into the hepatocytes15–20. The sodium taurocholate cotransporting poly-
peptide (NTCP) membrane transporter expressed by the hepatocytes has recently been reported as the functional 
HBV receptor. NTCP specifically interacts with the putative hepatocyte binding domain in the preS1 region of 
LHBs of HBV. NTCP can therefore serve as a target for developing therapeutic anti-HBV agents21–23. However 
the classical target, the viral hepatocyte binding domain has shown that anti-preS1(21–47 a.a.) agents such as 
antibodies are quite effective in neutralizing the virus by blocking its attachment, endocytosis and possibly mem-
brane penetration into the hepatocyte9–11,24. A number of highly specific murine and humanized preS1-specific 
monoclonal antibodies that effectively neutralize HBV infection in non-human primates have been generated9,10. 
The preS1 component has, therefore been incorporated into the third generation hepatitis B vaccines to achieve a 
stronger neutralizing response against the virus25.
Monoclonal antibodies (murine or chimeric), revolutionized the antibody based therapeutics, but the ability 
of these antibodies to generate human anti-murine antibody (HAMA) response makes them less preferred than 
humanized or human antibodies26. Recombinant human antibodies are promising alternative to these antibodies. 
These antibodies offer a major flexible advantage of gene manipulation and antibody engineering to produce anti-
body variants with better functional characteristics such as lower immunogenicity, higher affinity, specificity and 
enhanced stability27,28. Phage-displayed recombinant antibody libraries from human source (naïve, infected or 
recovered individuals), containing > 108–1010 antibody sequences can be generated and high affinity monoclonal 
antibodies can be screened from them against specific target antigens29,30. Immune libraries from spontaneously 
recovered individuals present a greater probability of obtaining high affinity and specific neutralizing antibodies.
High viral mutation rates along with subtle variations in viral genotype sequences may render the monoclonal 
antibody therapy less efficient. We therefore, aimed to generate an array of antibodies with overlapping binding 
specificities, broadly covering a single large epitopic region. In this article, we report the generation of potentially 
neutralizing preS1-specific recombinant human monoclonal scFvs from the peripheral blood lymphocytes of 
individuals spontaneously recovered from hepatitis B. Four scFvs with unique variable region sequences and 
binding sites were screened and each one showed a distinct molecular interaction pattern with the peptide. All 
four scFvs individually and even when used in combination were able to block binding of the preS1-peptide to 
hNTCP, the recently discovered hepatocyte receptor for HBV, in HepG2-hNTCP C4 cells. We suggest that the 
combined usage of these recombinant human antibodies may achieve broad spectrum neutralization and in addi-
tion provide better post-exposure prophylactic interventions for HBV infection.
Results
Anti-preS1 antibodies are present in the serum of spontaneously recovered individuals. We 
reasoned that individuals who have recovered naturally from hepatitis B infection would have clonally selected 
circulating memory B cells/plasma cells secreting highly specific neutralizing antibody against HBV. A flowchart 
that outlines the strategy used for the generation of preS1 specific monoclonal antibodies from a cohort of such 
patients is shown in Fig. 1A. Seven individuals with chance detection of anti-HBc antibodies during blood dona-
tion screening were further examined for hepatitis B infection markers. All the individuals tested positive for anti-
HBc and anti-HBs antibodies but were HBsAg and HBV DNA negative, and since none of them had any history 
of any therapy for the infection, they were recruited for the study. The results were consistent with the available 
literature and suggested a previous exposure to hepatitis B virus followed by natural recovery from the infection. 
Further analysis of the sera from these individuals for HBV specific antibodies was done using an indirect ELISA 
with immobilized HBsAg (containing S-protein only), purified recombinant preS1(60) and preS1(108) antigens 
and the preS1-peptide-KLH conjugate. This deciphering of the anti-HBs response showed that a strong anti-S 
protein response, which generally forms the memory response, was present in all the individuals. In addition, 
antibodies against preS1 region were also present which reacted with the recombinant full length preS1 protein 
(108 a.a.), truncated preS1 protein containing N-terminus 60 amino acids as well as the 28-mer preS1-peptide 
(21–47 a.a.). Anti-HBs as well as anti-preS1 antibodies were detected in the sera of all the individuals. Control 
serum from a healthy vaccinated individual (with only S-protein containing vaccine) did not show any preS1 
response but had elevated levels of anti-HBs antibodies (Fig. 1B).
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Phage displayed scFv library from naturally recovered individuals yields human anti-preS1 
antibodies. The presence of anti-preS1 antibodies in the sera of individuals naturally recovered from hep-
atitis B confirmed that the probability of obtaining preS1 specific neutralizing antibodies was high from these 
individuals. Amplification of the entire repertoire of heavy and light chains using RNA extracted from the PBLs of 
these individuals was carried out using a set of 31 consensus primers. The pooled VH and VL repertoire products 
( ~ 400 bp each) were linked by a flexible (Gly3Ser)4 linker to construct an scFv (visualized as a band of ~800 bp) 
(Fig. 2A). The scFv was further cloned into a phagemid vector (pAK100) to construct an immune phage dis-
played scFv library. Using 1 μ g ligation reaction and transformation into TG1 E. coli cells, we were able to obtain a 
compact scFv library consisting of ~1 × 105 different scFv molecules, while no clones were observed in no-insert 
ligation. Random screening of unselected library clones showed 100% insert frequency and also significant 
sequence variability on BstNI digestion and sequencing (data not shown). Biopanning of this library against the 
Figure 1. Generation of preS1 specific antibodies from naturally recovered patients. (A) Schematic 
overview of the generation of recombinant phage displayed monoclonal antibodies from naturally recovered 
hepatitis B patients. (B) The results of human serum ELISA with immobilized HBsAg VLPs, recombinant 
preS1(60), recombinant preS1(108) and the preS1-peptide-KLH conjugate. KLH was used as a control antigen 
while serum from a vaccinated individual (with the HBsAg S-protein only containing vaccine) was used as a 
healthy control. The cutoff value is shown in each graph by dotted line (mean + 2 S.D.) of the control samples.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:21240 | DOI: 10.1038/srep21240
Figure 2. scFv library construction and biopanning. (A) Representative figure showing the pooled VH 
and VL repertoires amplified from the RNA isolated from the blood of individuals naturally recovered from 
hepatitis B and the final constructed scFv which was cloned into pAK100 phagemid vector for scFv library 
generation. (B) Screening ELISA of 192 different phage clones (picked after third round of biopanning) against 
biotinylated preS1-peptide. The bound clones were detected using an anti-M13 HRP conjugated antibody. Anti-
preS1 polyclonal antibody was used as a positive control while VCSM13 helper phage was used as a negative 
control (Shown in black). Each bar represents an individual clone. Clones with mean values 2.1 fold greater than 
mean of negative controls were taken as positive binders. (C) Determination of sequence variability amongst the 
selected round 3 monoclonals using BstNI DNA fingerprinting of amplified scFvs. Four different fingerprinting 
patterns obtained from the screened 18 clones are underlined. (D) Phage ELISA of four antibodies selected 
after screening and BstNI fingerprinting, to different preS1 containing antigens: Native HBsAg; Biotinylated 
preS1-peptide; preS1-peptide-KLH conjugate and recombinant preS1(60) coated on a Nunc Maxisorb plate. 
The Rabbit anti-preS1 polyclonal antibody was used as a positive control while helper phage as a negative 
control. (E) ELISA of the soluble scFvs (using periplasmic extract) to preS1-peptide; HB2151 periplasm is used 
a negative control; anti-preS1-peptide (21–47 a.a.) rabbit polyclonal antibody was used as a positive control. For 
Fig. 2D,E, the cut-off values have been taken as mean of the control samples + 2(S.D.). (F) SDS-PAGE (upper 
panel)and western blotting (lower panel) of the four scFvs purified using Ni-NTA affinity chromatography.
(G) ELISA of the four scFvs with the preS1-peptide. Two fold dilutions of each scFv were incubated with the 
biotinylated preS1-peptide coated on a streptavidin coated plate and detected using anti-his rabbit antibody.
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preS1-peptide yielded more than 300 monoclonals which were screened against the biotinylated preS1-peptide 
by an indirect phage ELISA and high-binding specific scFv clones were identified (Fig. 2B). The best 18 high 
affinity clones were further analyzed for sequence variability using BstNI digestion. Among these eighteen scFvs, 
only 4 different fingerprinting patterns were observed; 14 out of 18 clones had similar fingerprinting patterns 
(similar to 2G3), while two other clones, 2E2 and 2B6, had identical fingerprints. Clones 2D9 and 2E7 had unique 
fingerprinting patterns (Fig. 2C). Phages from these four clones 2B6, 2D9, 2E7 and 2G3 were rescued, amplified, 
PEG precipitated and their binding analysis was performed with different preS1-containing antigens. Despite the 
complexity and source of the antigens used (plasma purified HBsAg, preS1-peptide-KLH conjugate and purified 
recombinant preS1(60) and preS1(108) antigens), all the antibodies bound specifically to the antigens that incor-
porated the preS1-peptide. The specific binding was confirmed by the lack of binding of these scFvs to the control 
antigens, KLH and Thioredoxin (Data not shown). The binding affinities of all the four phage-scFv (1012 phages/
well) were similar to different antigens in an indirect phage ELISA (Fig. 2D).
Properly folded, functional and soluble (phage-free) scFvs were obtained by expression of scFv-pAK400 con-
structs in the periplasmic space of HB2151 E. coli host. The periplasmic extract from all the clones showed specific 
high affinity binding to the biotinylated preS1-peptide in an indirect ELISA. Rabbit polyclonal antibody specific 
to the anti-preS1-peptide (21–47 a.a.) and HB2151 periplasmic extract were used as positive and negative controls 
respectively (Fig. 2E). Single step purification of the antibodies from the periplasmic fraction was carried out by 
Ni-NTA affinity chromatography but the overall yield of the purified scFvs was low; for purified 2B6, 2E7 and 2D9 
scFv the yield was  < 1 mg/L culture, while for purified 2G3 the yield was ~5 mg/L culture (Fig. 2F). For large scale 
production in a prokaryotic system, further engineering and manipulation of expression conditions of individual 
antibodies is required. The identity of the purified scFvs was confirmed by immunoblotting and detection using 
anti-6XHis antibody (Fig. 2F). Two-fold serial dilution of the purified antibodies was done and ELISA was carried 
out with the biotinylated preS1-peptide where all four scFvs showed similar binding characteristics despite their 
sequence variability (Fig. 2G).
Antibodies show differential germline usage and sequences. The antibody diversity at germline 
level is limited to a few germline sequences but during the affinity maturation process, mutations are accumulated 
in these sequences via rearrangement of V, D, and J segments, differential VH/VL pairing, addition or deletion 
at the junctional site and somatic hypermutation resulting in antigen-specific antibodies. The sequences of the 
four selected antibodies varied considerably and also, the CDRs accumulated more mutations in their sequences. 
Analysis of heavy and light chain germline usage among the four antibodies using V-Quest at IMGT31,32 (http://
www.imgt.org/IMGT_vquest/share/textes/) showed that all four scFvs were highly mutated in the variable region 
with respect to their germline counterparts.
A high ratio of replacement (R) to silent (S) mutations in an antibody sequence is indicative of the anti-
body undergoing somatic hypermutation process. The four scFvs showed differential heavy chain germline gene 
usage with IGHV6 being used in 2E7 and 2G3, while 2B6 and 2D9 scFvs used IGHV3 and IGHV4 respectively. 
Diversity of the VL part of the paratope was however smaller with only IGKV1 being represented in all but for 
one occurrence of IGKV3 (in 2E7 mAb). The 2G3 VH was found to be of highest homology with germline VH 
gene IGHV6-1*01 F with 92.2% identity in terms of nucleotides. A total of 29 mutations were observed with 18 
replacement (R) and 11 silent (S) mutations in a ratio of 9/3 and 9/8 (R/S) for CDRs and FRs, respectively. The 
2G3 VL shows 87.46% identity (at nucleotide level) with the germline light chain gene IGKV1-12*01. Out of the 
total 38 nucleotides changed from germline genes, 27 cause replacement mutations in the V-region (nine of 
which are clustered in CDRs). The R/S mutation ratio for light chain are 10/4 and 17/7 for CDRs and FRs respec-
tively. 2B6 VH was a result of recombination between Homsap IGHV3-11*01 V-gene (89.9% homology), Homsap 
IGHJ1*01 J-gene (84.78% homology) and Homsap IGHD2-2*01 D genes. The productive 2B3VL resulted from 
a recombination between Homsap IGKV1-12*01 (91.4% homology) and Homsap IGKJ3*01 (89.4% homology) 
from the V and J-regions respectively. 2D9 VH and VL have high homology of approximately 97% each (at nucle-
otide level) to their germline counterparts. Heavy chain gene may have originated from the recombination of 
IGHV4-b*02 F, Homsap IGHJ5*02 F and Homsap IGHD7-27*01 F genes while the recombining V and J genes in 
2D9 VL are Homsap IGKV1-27*01 and Homsap IGKJ1*01 F respectively. The homology search identified Homsap 
IGHV6-1*01 F as the V-gene allele with a homology of 95.2% to 2E7VH while the recombining J and D genes were 
identified as Homsap IGHJ6*02 F and Homsap IGHD1–14*01 respectively, showing an identity of 80%. The light 
chain was a result of recombination between Homsap IGKV3–20*01 F (93.26% homology) and Homsap IGKJ2*01 
F (84.62% homology) genes from V and J regions respectively.
The R/S mutations in the heavy chain of 2B6, 2D9 and 2E7 are 23/8, 7/2 and 12/8 respectively, while that 
for the light chain are 20/9, 5/6 and 17/7 respectively. The number of replacement and silent mutations and the 
germline genes of the heavy and light chains of all the four scFvs have been summarized in Fig. 3 and Table 1.
Molecular modeling of the anti-preS1 antibodies and preS1-peptide. In the absence of solved 
crystal structures, near-native structures of antibodies and antigens can be deciphered by molecular modeling 
based on homology with known structures. Web-based molecular modeling server, web antibody modeling 
server, WAM33 (http://antibody.bath.ac.uk/) was used for the generation of molecular models for 2D9 and 2G3. 
WAM model could not be predicted for 2E7 and 2B6 since the vernier residues in these scFvs were not con-
served. Prediction of Immunoglobulin Structure, PIGS34 (http://arianna.bio.uniroma1.it/pigs) server was used 
for building the scFv model using default parameters for these scFvs. The CDRs of all scFvs attained the charac-
teristic loop structures, forming distinct antigen binding pockets with unique surface topology. Figure 4 shows 
the cartoon representation of the four antibodies with highlighted CDRs. The structural model for preS1-peptide 
(21–47 a.a.) was predicted by the web based molecular modeling server, i-Tasser35 (http://zhanglab.ccmb.med.
umich.edu/I-TASSER/). Model1 was the best predicted structural model with a confidence score (C-score) of 
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1.94; TM-score = 0.48 ± 0.15; RMSD 5.3 ± 3.4 Å by the server. The molecular model analyzed by Pymol showed 
that the peptide attained a loop conformation in solution and any other secondary structures were absent.
Differential interactions of preS1-peptide residues with selected HuMAbs. To study the detailed 
molecular interactions involved in peptide recognition by the four antibodies, docking experiments were carried 
out using the modeled peptide and the WAM/PIGS model of the scFv on the antigen-antibody interface of the 
Figure 3. PreS1-peptide-scFv interactions. (A–D) Panel 1: The replacement (R) and substitution (S) 
mutations in each clone at the nucleotide level in the variable region of the antibodies. Panel 2: The molecular 
models of four scFvs. CDRs loops forming antigen binding sites of different topology in each scFv are 
highlighted. Panel 3: Ball and stick representation of the preS1-peptide-scFv interaction. The interacting 
residues of the heavy chain are shown in green while the light chain residues are in blue while the peptide is 
represented as red. The dotted lines show the interactions of the peptide and scFv residues in each case. (E) A 
summarized model of broad coverage of entire preS1-peptide region (21–47 a.a.) by recognition of overlapping 
epitopes by the four scFvs.
www.nature.com/scientificreports/
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web based docking server ‘Patchdock’36 (http://bioinfo3d.cs.tau.ac.il/PatchDock/). Figure 4 gives a ball and stick 
representation of the interacting residues of the peptide and the four scFvs. The predicted interacting residues 
have been listed in Table 2. Seven residues of 2G3 from three different CDRs and one FW region contributed to 
the overall interaction with five residues of the peptide. CDRH2, CDRH3 and CDRL3 loops formed the antigen 
binding pocket with one vernier residue from the FW4 contributing to the lone FW interaction with the peptide. 
The residues from CDRH2 loop are predicted to provide the maximal contribution to peptide binding with 3 
CDRH2 residues forming polar contacts with the residues of preS1-peptide.
The putative epitopic footprint of the 2B6 antibody spans from residue 16–27 on the preS1-peptide which is 
distinct from 2G3 epitopic footprint. The CDRH2 and CDRL3 provide the major contributions towards anti-
gen binding with 2 and 3 residues from FRL1 and FRH3 respectively also putatively interacting with the preS1 
peptide.
The predicted epitopic footprint of the 2D9 mAb is similar to 2B6 but the peptide interacting residues are 
fewer. The Asn17 residue from the peptide interacts with two CDRH2 residues while the CDRH1 residue H34Tyr 
interacts with the Asn20 on peptide. Two light chain residues from CDRL3 form an H-bond each with the Asp22 
residue while the CDRL1 residue L28Gly interacts with Pro27 residue on the peptide.
The docking studies further predicted that 2E7 scFv forms only 3 bonds with the peptide spanning the resi-
dues 18–27. The Pro27 residue which is common interacting partner of the 2B6 and 2D9 also interacts with the 
2E7 residue H57Asn from CDRH2 while two Ser residues from CDRL1, interact with Ser18 and Asn19 residues 
on the peptide respectively. The number of interactions formed by different antibodies is different but the binding 
strength of all the antibodies is similar.
In vitro ‘surrogate neutralization assay’ shows inhibition of peptide-hNTCP interaction by 
scFv antibodies. The in vitro assays to determine the neutralizing potential of the anti-HBs antibod-
ies employ cells that are permissive to HBV infection and express the functional HBV receptor, hNTCP, on 
their surface (differentiated human or Tupaia hepatocytes or HepaRG cell line). Cell lines such as Huh7 and 
HepG2 retain hepatocyte specific surface markers and allow HBV binding through preS1 region (21–47a.a.) 
but are not a good model due to low expression levels of hNTCP. We therefore used a cell line stably trans-
fected with hNTCP (HepG2-hNTCP-C4) for our study. The stable cell line showed higher expression levels of 
the functional HBV receptor, hNTCP (Fig. 4A,B) and has been shown to be permissive to HBV infection. Using 
HepG2-hNTCP-C4cells, we have established fluorescence microscopy and flow cytometry based ‘surrogate 
in vitro neutralization assay’ to determine the ‘neutralizing potential’ of preS1 specific antibodies. The ability of 
these antibodies to block the binding of rec-preS1(60) (Fig. 4C) to the HepG2-hNTCP-C4 cells was taken as a 
measure of their ‘neutralization potential’. HepG2-hNTCP-C4 cells were incubated with the rec-preS1(60)-FITC 
conjugate (1 μ M). Treatment of the cells with pre-incubated mixture of rec-preS1(60)-FITCand the four scFvs, 
2B6, 2D9, 2E7 and 2G3 (10 μ M each) individually or as a cocktail (equimolar ratio; 2.5 μ M each) showed varying 
degrees of inhibition of HepG2-hNTCP-C4-preS1(60) interaction (number of FITC stained cells) as evident by 
the peak shift (from stained population to unstained) in the histogram (Fig. 4D). The number of FITC stained 
cells was reduced in each case as compared to the cells treated with rec-preS1(60)-FITC alone. Amongst the 
scFvs, 2E7 showed the best inhibition individually in comparison to 2G3, 2B6 or 2D9. The positive controls, 
anti-preS1(21–47a.a.) rabbit polyclonal antibody and commercial anti-preS1 mAb raised against preS1 peptide 
(21–47a.a.) also showed inhibition of the preS1 interaction with cells to a similar extent as shown by the scFv 
cocktail, while an unrelated mAb, 1A7 showed no inhibition at all. The fluorescence microscopy was carried out 
on an Olympus Laser Confocal Scanning Microscope (FV1000D) using a 60 × oil objective. The cells were seeded 
on collagen coated coverslips and treated as done for flow cytometry. The results obtained were in consistence 
with the flow cytometry data where a high degree of inhibition was achieved using the scFvs as well as cocktail of 
four antibodies (Fig. 5). The controls also provided consistent results with anti-preS1 mAb and anti-preS1 RpAb 
showing inhibition of preS1-NTCP interaction while no inhibition was evident with the unrelated mAb 1A7. The 
results provide a proof of concept for better coverage of a broad epitope using a cocktail of antibodies as against 
the conventional single monoclonal antibody use.
Discussion
Neutralizing antibodies have rapidly become a clinically important drug class for prophylaxis of several infectious 
diseases where they can confer post-exposure protection against the infection37,38. Blood purified HBIG, alone or 
in combination with hepatitis B vaccine, is advocated as an adjunct therapy for post-exposure hepatitis B proph-
ylaxis5,7. However, due to the low specific activity of HBIG and emergence of newer HBV ‘escape’ variants which 
HuMAb clone
Germline genes
VH VL
V D J V J
2B6 IGHV3-11*01 IGHD2-2*01 IGHJ1*01 IGKV1-12*01 IGKJ3*01
2D9 IGHV4-b*02 IGHD7-27*01 IGHJ5*02 IGKV1-27*01 IGKJ1*01
2E7 IGHV6-1*01 IGHD1-14*01 IGHJ6*02 IGKV3-20*01 IGKJ2*01
2G3 IGHV6-1*01 IGHD3-10*02 IGHJ4*02 IGKV1-12*01 IGKJ4*01
Table 1.  Analysis of HuMAbs selected against preS1-peptide region (21–47a.a.) for their germline origin.
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can persist despite previous immunization, this therapy is frequently rendered ineffective. This underlines the 
need for better measures for passive prophylaxis39,40.
Antibodies targeting various epitopes in the immunodominant S region and the pre-S region of the HBV 
surface antigen have shown promise as neutralizing agents10,41. Different research groups have mapped the HBV 
Figure 4. (A) NTCP expression levels in the HepG2 cells and the HepG2-hNTCP-C4 cells using real time PCR. 
(B) Western blot showing the relative NTCP protein expression levels in the two cell lines; Bottom panel: Beta-
actin for both the cell lysates. (C) Schematic showing PreS1 (N-terminus 60 amino acids) and the location of 
the peptide between 21–47 amino acids. (D) Representative flow cytometry experiment showing binding of the 
preS1-peptide to the HepG2-hNTCP-C4 cells and inhibition of the preS1-peptide-hNTCP interaction by the 
four antibodies individually and as a cocktail. The rabbit polyclonal antibody to preS1peptide (21–47 a.a.), anti-
preS1 RpAb, and a commercial anti-preS1 mAb were taken as positive controls while an unrelated mAb, 1A7, 
was taken as a negative control. Student’s t-test was used for the statistical analysis and p-values < 0.05 were 
considered significant.
2G3 2B6 2D9 2E7
Peptide 
residue
scFv 
residue Location
Peptide 
residue scFv residue Location
Peptide 
residue scFv-residue Location
Peptide 
residue
scFv 
residue Location
Ser 18 H99Asp CDRH3 Asn17 L1Glu, L2Thr FRL1 Asn17 H56Ser, H57Thr CDRH2, CDRH2 Asn19 L27ASer CDRL1
Gly3 H50Arg CDRH2 Asn20 H61Asp, H64Lys FRH3 Asn20 H34Tyr CDRH1 Ser18 L29Ser CDRL1
Gly3 H52Tyr CDRH2 Asp22 H64Lys FRH3 Asp22 L91Tyr, L93Ser CDRL3, CDRL3 Pro27 H57Asn CDRH2
Gly3 L91Val CDRL3 Asn26 H52Ser CDRH2 Pro27 L28Gly CDRL1
Phe4 L94Phe CDRL3 Pro27 H52Ser CDRH2
Asp11 H53Ser CDRH2 Ala16 L92Asp CDRL3
Asp7 H56Tyr FRL3 Ser18 L95Pro CDRL3
Table 2.  Interacting residues of the preS1-peptide and heavy and light chains of the four scFvs.
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Figure 5. (A) Fluorescence microscopy images (using confocal microscope) showing inhibition of peptide-
HepG2-hNTCP-C4 cell interaction by the four scFvs (2B6, 2D9, 2E7 and 2G3) individually, and as a cocktail. 
The peptide pre-incubated with the respective antibodies was allowed to bind to the HepG2-hNTCP-C4 
cells. A rabbit polyclonal antibody to preS1peptide (21–47 a.a.) and a commercial anti-preS1 mAb were taken 
as positive controls while an unrelated mAb, 1A7, was taken as a negative control. The first panel shows the 
DAPI image, second panel shows FITC image and the third panel shows the merged image captured using 
60 × objective lens for each treatment (Scale = 10 μ m).
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preS1 domain involved in receptor recognition but the HBV preS1 region between residues 21–47 is considered 
crucial for attachment and uptake of the virions into the hepatocytes15,16,18,19. A peptide spanning this pre-S1 
region has been used as a hepatocyte targeting agent and demonstrated to inhibit viral binding to human hepatic 
cells42. PreS1 (21–47 a.a.)-specific antibodies have been shown to be effective in prevention of hepatitis B infection 
in non-human primates (NHPs). Third generation vaccines therefore incorporate a preS1-component to generate 
a better immune response10,24,43. Antibodies which emerge during the course of acute HBV infection in patients 
are neutralizing and also initiate HBV clearance. The anti-preS1 responses are taken as a measure of the adequacy 
of patient’s anti-HBV response and usually precede the responses to S protein but diminish within few months 
after viral clearance13,44,45. For the assessment of spontaneous recovery from hepatitis B infection in our study, we 
considered positivity for viral sero-markers - anti-HBc and anti-HBs along with negative HBV-DNA and HBsAg 
in individuals who had no medical history for anti-HBV therapy46. We detected antibodies against S as well as 
preS1 antigens in these individuals; however, the titers for anti-HBs antibodies were higher in comparison to 
anti-preS1 antibody titers. Antibodies detected against the preS1-peptide (21–47 a.a.) in the sera were indicative 
of a protective immune response. The time interval between sample collection and infection was unknown, and 
the low levels could be due to waning of anti-preS1 responses following recovery45. The presence of anti-preS1 
antibodies in the serum of these individuals was confirmatory of a recent episode of acute hepatitis B infection 
followed by recovery and corroborated with previous reports44,47.
Human monoclonal antibodies have been isolated from PBMCs of healthy individuals or human volunteers 
immunized with the isolated antigen or from successfully treated/naturally recovered patients using hybridoma/
phage display technology30,48,49. Our selected cohort of individuals presents a reasonable probability of obtain-
ing neutralizing antibody. A medium sized phage displayed scFv library was constructed from the RNA of the 
circulating lymphocytes of these individuals and biopanning and screening of this library yielded four distinct 
monoclonal antibodies. The four scFvs- 2B6, 2D9, 2E7 and 2G3 had unique sequences but showed similar bind-
ing towards the preS1-peptide and the preS1 containing recombinant as well as blood derived antigens. These 
similar specificities but differing interactions of the four validated mAbs can be attributed to differential germline 
gene usage and evolution through somatic hypermutations under a rigorous selection pressure for preS1 anti-
gen during affinity maturation process. Affinity maturation involves efficient and productive change of germline 
Tryptophan, Serine and Tyrosine residues with promiscuous binding residue types in the antigen binding site that 
confer specificity towards a particular antigen50,51. The absence of Tryptophan and Tyrosine amongst the peptide 
interacting residues of the four mAbs is indicative of accumulation of somatic hypermutations in the antibody 
genes. The differential germline usage amongst the antibodies was reflected in the usage of IGHV6 in 2E7 and 
2G3, and IGHV3 and IGHV4 respectively, in 2B6 and 2D9 scFv heavy chains. The diversity in VL germline gene 
usage was limited to IGKV1 with only 2E7 utilizing IGKV3 gemline light chain gene. Germline analysis also 
revealed significant genetic variations, especially in the CDRs and FRs, characterized by a high replacement to 
substitution mutations (R/S) ratio52.
Structural or computational studies provide useful insights into the rational design of novel therapeutic strat-
egies53. It has been observed that a broadly neutralizing monoclonal antibody identifies its signature epitope 
and generates a selective immune pressure under which the viruses tend to undergo antigenic drift. This leads 
to viral mutations at sites that identify the antibody binding site and generation of antibody resistant ‘escape 
mutants’ which limit the efficacy of monoclonal antibody therapy54,55. Therefore, a broad and potent polyclonal 
humoral response against multiple neutralization epitopes is required to control preexisting viral mutants and 
to limit viral evolution. The in vivo immune response against the hepatitis B virus is also polyclonal in nature 
involving the neutralizing epitopes13. Distinct antibodies have differing conformations of the binding site and 
utilize discrete interaction patterns to recognize a similar epitopic region. This multifaceted viral recognition by 
antibodies reduces the possibility of viral escape56. Docking of the four human mAbs 2B6, 2D9, 2E7 and 2G3 with 
the preS1-peptide revealed the detailed molecular interactions. Discrete but overlapping set of preS1-peptide 
residues which span the entire 28-mer peptide were recognized by the four scFvs and provided broad coverage of 
the defined hepatocyte interaction domain of HBV. The targeted preS1 epitope (21–47 a.a.) is indispensable for 
the viral infection process and is evolutionarily conserved with minimal variations amongst the viral genotypes. 
Our findings lend support to the hypothesis that for a broad and better prophylactic intervention against HBV, a 
panel of antibodies against preS1 region should be used as they would mimic natural immune response providing 
a broader coverage of viral attachment site.
Although human or tupaia hepatocytes have been frequently used, lack of established cell lines has hampered 
HBV attachment and replication studies. Host specificity and tissue tropism of HBV are attributed to its specific 
receptor recognition. Identification of NTCP as a host entry receptor for HBV has vastly enhanced the knowledge 
of HBV entry and infection process and also paved the way towards development of new host-directed antivirals. 
The NTCP is significantly expressed in HBV-susceptible cells, PHH and differentiated HepaRG cells but is weakly 
expressed in hepatic cell lines such as HepG2 and Huh-7 which are refractory to productive HBV infection. 
It has been demonstrated that overexpression of NTCP in these cell lines can make them susceptible to HBV 
infection21–23. The viral entry process is an attractive target for the development of antiviral agents. Neutralizing 
antibodies exert antiviral activities by blocking viral entry into cells and/or accelerating viral clearance from cir-
culation41. Flow cytometry and fluorescence microscopy based ‘surrogate in vitro neutralization assays’ that we 
used were based on inhibition of peptide attachment to HepG2-hNTCP-C4 cells by the antibodies. The assays 
provide a rapid, virus-free platform for the assessment of neutralizing efficacy of anti-preS1 antibodies. Our 
results suggest that while all the antibodies were able to inhibit peptide attachment to the HepG2-hNTCP-C4 cells 
individually, the combined use of these antibodies could educe an equivalent but broader neutralization with a 
coverage of a larger epitope region in the surrogate in vitro neutralization assays. The antibody panel generated 
in this study may also have a therapeutic value in established infection. Similar combined usage of antibodies has 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:21240 | DOI: 10.1038/srep21240
proven effective as a post-exposure prophylactic for lethal viral diseases with no approved vaccine such as HIV 
and especially Ebola virus infection in non-human primates37,57.
Vaccine or drug induced viral escape mutants along with multiple viral subtypes are the major contribu-
tors towards the global prevalence of hepatitis B4,40. Spontaneously recovered individuals have natural neutral-
izing antibodies in their blood and we present a method to efficiently harness these natural human antibodies. 
Though we have not explored the idea in vivo, the marked difference in the antibody sequences resulting in very 
distinct epitope-paratope interactions raises the possibility that use of a cocktail of antibodies would be more 
tolerant to genotypic variations/mutations in the preS1 region. We propose that while mimicking the natural 
polyclonal response, such panel of antibodies would provide us with an efficient and well characterized way of 
viral neutralization.
Methods and Materials
Reagents. The vectors pAK100 and pAK400 were received as a kind gift from Dr. Andreas Plückthun, 
Department of Biochemistry, University of Zurich, Zurich, Switzerland. Yashraj Biotech, India provided the 
purified blood-derived native HBsAg as a gift. E. coli strains TG1 and HB2151 were obtained from Amersham 
Biosciences.
Cell culture. HepG2-hNTCP-C4 cells were cultured in collagen coated flasks (0.1 mg/mL collagen [Sigma, 
C3867]) as described earlier at 37 °C in a humidified incubator containing 5% CO2. The growth media consisted 
of HEPES buffered DMEM (Invitrogen, 2320032) supplemented with 200 units/ml penicillin, 200 μ g/ml strep-
tomycin (Gibco, 15140-122), 10% FBS (Gibco, 16000-044), 50 μ M hydrocortisone (Himedia, TC344), 5 μ g/ml 
insulin (Himedia, TC190) and 400 μ g/ml G418 (InvivoGen, ant-gn-1).
Construction of human scFv library. Selection criteria and serum ELISA. All ethical approval for the 
study was obtained from the institutional (AIIMS, New Delhi) ethics committee (IESC/OT-02/02.07.10). All 
methods were carried out in accordance with the approved guidelines of the AIIMS ethics committee. Also it is 
confirmed that an informed consent was obtained from all the subjects before enrolment into the study.
Individuals who had naturally recovered from hepatitis B but were on routine check-up in the Liver clinic 
of All India Institute of Medical Sciences (AIIMS) were recruited. The selection criteria included chance detec-
tion cases with positivity for anti-HBc and anti-HBs antibodies but with no detectable amounts of HBsAg or 
HBV-DNA and no history of therapy for infection. 10 ml blood collected from all the individuals (n = 7), was 
used for serum separation as well as peripheral blood lymphocyte (PBL) isolation (using Histopaque-1077). For 
serum ELISA, serum (1:100) was incubated with the antigens immobilized on Nunc maxisorp plates (Nunc, 
442404) at 37 °C for 1 hour and the bound IgG antibodies were detected using anti-human IgG-HRP conjugate 
(1:5000) and substrate OPD.
Phage displayed single chain variable fragment (scFv) library construction. RNA isolated from PBLs was reverse 
transcribed to cDNA and the entire variable region repertoires of human heavy and light chains were amplified 
using consensus forward and reverse primers using multiple PCR reactions for each chain (24 reactions for VH, 
21 for VLλ and 30 for VLκ ). The heavy and light chain primers (IDT) were modified from primers reported by 
Pansri et al., 2009, wherein the NotI restriction site was replaced by SfiI restriction site. Separate pools of VH, VLλ 
and VLκ repertoires were made by pooling amplified variable region products (~400 bp). The scFv (~800 bp) was 
constructed by overlapping the VH and VL pools with a flexible linker (Gly4Ser)3 using ‘Assembly PCR’ and Final 
‘Pullthrough’ PCR. The final library was constructed by ligating the scFv into pAK100 phagemid vector, transfor-
mation into TG1 competent cells and pooling together the resulting colonies30,58,59.
Biopanning. The phage rescue from the constructed library was carried out as described earlier using 
VCSM13 helper phage (Stratagene, 200251)58. Three rounds of biopanning were carried out using biotinylated 
preS1-peptide (5 μ g/ml) immobilized on high binding streptavidin coated plates (Pierce, 15501). Library phages 
(~1 × 1012) were incubated with the peptide and unbound phages were washed out with PBST (0.1%). The bound 
phages were eluted using 100 μ l of 200 mM glycine-HCl, pH 2.2 and neutralized using 15 μ l 1 M Tris-HCl, pH 
9.1. The eluted phages were infected into mid-exponential phase (OD600 ~ 0.4) TG1 cells and grown for 1 hour at 
37 °C and plated on 2 × YT/ Chloramphenicol/2%Glc/ Agar plates and incubated overnight at 37 °C. Washing 
stringency was gradually increased over each round (Round 1–0.1% Tween-PBS × 10 washes; Round 2–0.3% 
Tween-PBS × 15 washes; Round 3–0.5% Tween-PBS × 20 washes) to wash out the low affinity phages. The num-
ber of input and output phages for each round was calculated by making a transformation unit count. The colo-
nies obtained after the third round were individually grown as monoclonals.
Screening and characterization of scFv clones. For screening, 100 μ l of supernatant containing rescued 
phage from each monoclonal (scFv) was added to the blocked streptavidin-coated plate coated with biotinylated 
preS1-peptide (5 μ g/ml) and incubated for 1 hour at 37 oC. Post washing, the bound phage was detected using 
100 μ l of anti-M13 HRP-conjugated antibody (GE lifesciences, 27942101) (1:2000) using TMB as substrate. For 
further characterization, the phage containing supernatant was precipitated using PEG/NaCl and used in ELISA 
in a concentration of 1 × 1012 phages/100 μ l.
The scFv gene of selected scFvs was cloned into pAK400 vector and transformed into HB2151 E. coli cells 
for periplasmic expression. The scFv clone was then grown in 1L 2xYT/Chloramphenicol media and induced at 
an OD~0.8 with 1 mM IPTG (Amresco, 0487) for 15 hours at 20 °C, 250 rpm. The periplasmic extract was pre-
pared using ‘Osmotic Shock method’60. 100 μ L of supernatant was added to the preS1-peptide coated streptavi-
din plate and incubated for 1 hour at 37 °C. Post washing, bound phages were detected using 100 μ l of anti-his 
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antibody (1:2000) (Cell Signaling Technologies, 3724) and anti-rabbit HRP-conjugated antibody (Cell Signalling 
Technologies, 70745) using TMB as substrate.
Protein Purification and labeling. Recombinant preS1 antigens: preS1(60) and preS1(108) were cloned 
in pET32a + vector between NcoI and XhoI restriction sites and the expression constructs were transformed 
into BL21(DE3) E. coli cells. The antigens were expressed in 2× YT culture medium containing ampicillin and 
induced at O.D. ~ 0.8 with 1 mM IPTG at 20 °C for 15 hours. The recombinant proteins were purified from the 
soluble (cytoplasmic) fraction in a single purification step by Ni-NTA affinity chromatography. FITC labeling of 
the purified preS1(60) was done using a commercial kit (Thermo Scientific, 53027) according to manufacturer’s 
instructions. For scFv purification, periplasmic fraction of HB2151 E. coli cells transformed with scFv-pAK400 
expression construct was utilized. The scFvs were purified using his-tag by Ni-NTA affinity chromatography.
Molecular modeling of antibody fragments (scFvs) and preS1-peptide. The sequencing of the 
scFvs was done by Invitrogen using pullthrough primers. The antibodies were numbered as per Kabat rule. 
The germline sequences of VL and VH were analyzed by online V-Quest software provided by the international 
ImMunoGeneTics database (IMGT)31,32 (http://www.imgt.org/IMGT_vquest/share/textes/). The localization of 
Complementary Determining Regions (CDRs) and Framework regions (FRs) were analyzed for their percent 
variation and mutation from the original germline sequence.
Molecular models of the scFvs were generated by web based antibody modeling software WAM33 (http://anti-
body.bath.ac.uk/) using ‘dead end elimination’ algorithm for side chain building and Valence Force Field (VFF) 
screen for final screening. In cases where WAM model could not be predicted, the Prediction of ImmunoGlobulin 
Structure (PIGS) server was used for building the scFv model using default parameters34 (http://arianna.bio.
uniroma1.it/pigs). The molecular model of preS1-peptide was predicted using I-TASSER of threading method35 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/). The server generated five models and the best one was 
selected based on C-score. All the predicted models were viewed and analyzed in Pymol viewer.
Molecular Docking of the pre-S1 peptide and scFvs. Web based server ‘PatchDock’ was used for 
the peptide-scFv docking studies36 (http://bioinfo3d.cs.tau.ac.il/PatchDock/). Molecular models of scFv and 
preS1-peptide were used as input in the antigen-antibody docking algorithm. Twenty models were generated 
by the server and the top ten solutions with a near-native conformation were identified. The server ranked the 
models on the basis of geometric score, desolvation energy, interface area size and the actual rigid transformation 
of the solution. The highest ranked model was selected for analysis.
Cellular binding inhibition assays. HepG2-hNTCP-C4 cells (~5 × 104 cells) were grown on 12-mm cov-
erslips coated with 0.1 mg/mL collagen (Sigma) for 24 hours, washed with 1 × PBS and incubated with either 
1 μ M preS1(60)-FITC protein or with preS1(60)-FITC -scFv mixtures at room temperature for 30 min. The 
preS1(60)-FITC protein (1 μ M) and the scFv (10 μ M for each scFv or control antibodies) were pre-equilibrated 
for 1 hour at room temperature in DMEM containing 0.5% FBS. (For Cocktail, each scFv was taken at a concen-
tration of 2.5 μ M to get a final cocktail concentration of 10 μ M). The cells were washed with PBS three times, fixed 
with 4% (w/v) paraformaldehyde (PFA) and the coverslip was mounted using Fluoroshield™ mounting media 
with DAPI (Sigma, F6057) on a glass slide. The fluorescence microscopy was performed on an Olympus Laser 
Confocal Scanning Microscope (FV1000D) using a 60 × oil objective.
For flow cytometry experiments, 5 × 104 cells were seeded in collagen coated 24-well plate (Corning, 354408), 
grown at 37 °C for 24 h, treated and fixed similar to confocal microscopy. The samples were acquired using FACS 
Verse flow cytometer (BD Biosciences) and the analysis was performed on FlowJo software.
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